Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons [Phase 1]

View source ↗

Summary

Phase 1 trial comparing the pharmacokinetics and pharmacodynamics of BIOD-961 against marketed glucagon in hypoglycemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia

Drugs mentioned

• BIOD-961
• glucagon (marketed) (glucagon)

Snippet

Sponsor: Biodel | Conditions: Hypoglycemia | Phase 1 | Status: COMPLETED